Working… Menu

An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01678690
Recruitment Status : Completed
First Posted : September 5, 2012
Last Update Posted : September 2, 2016
Information provided by (Responsible Party):
InnoPharmax Inc.

Brief Summary:
Open-label, Phase 0, dose-escalation study of 3 successive cohorts (3 subjects per cohort), to determine and characterize the plasma PK of gemcitabine HCl oral formulation (D07001-F4) administered once on Day 1 with 7 Days of study follow-up. In addition, oral tolerability and safety will also be assessed during this 1-week period.

Condition or disease Intervention/treatment Phase
Malignant Tumors Drug: Gemcitabine HCl Oral Formulation Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: An Open-Label, Exploratory, Limited Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
Study Start Date : August 2012
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Gemcitabine HCl Oral Formulation
Subjects will be treated with Gemcitabine HCl Oral Formulation according to assigned cohort (2 mg or 5 mg or 10 mg) on Day 1 of the 7-day study treatment period
Drug: Gemcitabine HCl Oral Formulation
Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
Other Name: D07001-F4

Primary Outcome Measures :
  1. gemcitabine (dFdC) and difluorodeoxyuridine (dFdU) plasma concentration and gemcitabine triphosphate (dFdCTP) concentration in PBMC [ Time Frame: Day 1-5 ]

Secondary Outcome Measures :
  1. the proportion of subjects experiencing adverse events all grades, change from baseline in clinical laboratory test results, vital sign measurements, and physical examination findings [ Time Frame: Day 1-8 (+/- 1) days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female subjects aged 18 years and older.
  2. Signed and dated informed consent form.
  3. Subjects with malignancies with histological or pathologic confirmation and who are clinically stable.
  4. History of treatment with at least 1 cytotoxic chemotherapy regimen for the current malignancy.
  5. If the subject has received cytotoxic chemotherapy within the past 14 days, the subject is beyond the nadir of white blood cell and platelet counts.
  6. At least 28 days have elapsed since the subject's prior radiotherapy or any major surgery (excluding diagnostic biopsy or venous access device placement).
  7. World Health Organization (WHO) performance status 0 to 2
  8. Subject has an ANC ≥1500 cells/mm³, platelet count ≥ 100,000 cells/mm³, and hemoglobin ≥ 9 g/dL.
  9. Subject has adequate liver function demonstrated by transaminases within normal limits (aspartate transaminase and alanine transaminase), total bilirubin ≤ 1.5 mg/dL (unless due to Gilbert's syndrome), albumin ≥ 2.5 g/dL, international normalized ratio [INR] < 1.5).
  10. Subject has adequate renal function: serum creatinine ≤ 1.5 x upper limit of normal.
  11. Subject has a life expectancy >24 weeks.
  12. If a women of child-bearing potential, subject has a negative pregnancy test and is not breast-feeding.
  13. If a women of child-bearing potential, subject is using a medically acceptable form of birth control prior to screening and for the duration of their study participation and for 1 month after the end of the study.
  14. Subject is willing to comply with protocol-required visit schedule and visit requirements and provide written informed consent.

Exclusion Criteria:

  1. Subject has rapidly progressive disease or rapid clinical deterioration as assessed by the Investigator.
  2. Subject is receiving full-dose (therapeutic) anticoagulation therapy.
  3. Subject is receiving concomitant radiotherapy.
  4. Subject is intolerant or allergic or has a known hypersensitivity to gemcitabine.
  5. Subject has clinically significant cardiovascular disease (for example: uncontrolled hypertension, unstable angina, congestive heart failure, or New York Heart Association Grade 2 or greater).
  6. Subject has uncontrolled serious cardiac arrhythmia.
  7. Subject has known active brain metastases, or any leptomeningeal metastases.
  8. Subject has a history of drug or alcohol abuse within last year.
  9. Subject has documented cerebrovascular disease.
  10. Subject has a seizure disorder not controlled on medication.
  11. Subject received an investigational agent within 30 days of screening.
  12. Subject received systemic treatment for infection within 14 days of screening.
  13. Subject has known human immunodeficiency virus infection or viral hepatitis.
  14. Subject has any other serious medical condition that, in the investigator's medical opinion, would preclude safe participation in a clinical trial.
  15. Subject has gastrointestinal disease or prior gastrointestinal surgery that may interfere with adequate oral therapy absorption.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01678690

Layout table for location information
United States, Georgia
Georgia Regents University- Cancer Center
Augusta, Georgia, United States, 30912
United States, Ohio
Gabrail Cancer Center Research
Canton, Ohio, United States, 44718
Gabrail Cancer Center Research
Dover, Ohio, United States, 44622
National Taiwan University Hospital
Taipei, Taiwan, 10048
Sponsors and Collaborators
InnoPharmax Inc.
Layout table for investigator information
Principal Investigator: Nashat Y. Gabrail, MD Gabrail Cancer Center Research
Principal Investigator: Sharad Ghamande, MD Augusta University
Principal Investigator: Chia-Chi Lin, MD National Taiwan University Hospital
Layout table for additonal information
Responsible Party: InnoPharmax Inc. Identifier: NCT01678690    
Other Study ID Numbers: HR-11-001
First Posted: September 5, 2012    Key Record Dates
Last Update Posted: September 2, 2016
Last Verified: August 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs